<DOC>
	<DOCNO>NCT00134251</DOCNO>
	<brief_summary>This study multicenter , randomize , double-blind , placebo control , parallel group study seven-week ascend dose period SLV308 adjunctive L-dopa treatment patient advanced stage Parkinson 's disease ( PD ) dose-dependent motor fluctuation . Patients ( outpatient ) randomize one three different treatment arm .</brief_summary>
	<brief_title>Ascending Dose Tolerability/Safety SLV308 Treatment Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients sign informed consent ; diagnosis idiopathic PD . Presence recognizable `` '' `` '' stag Minimum hour `` '' time per day 2.5 hour Able keep diary . Unclear diagnosis suspicion parkinsonian syndrome Have undergone surgical treatment PD History nonresponse Ldopa .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>adjunctive L-dopa therapy</keyword>
	<keyword>Advanced stage Parkinson 's disease</keyword>
</DOC>